The Big Bold Health Longevity Study: Himalayan Tartary Buckwheat, Immune Aging, and the 47% Finding

There are plenty of longevity supplements with theories behind them.

Far fewer have been put into a human clinical study and examined with hundreds of thousands of DNA methylation measurements.

That is what makes the Big Bold Health Longevity Study worth a closer look.

The paper, published in Frontiers in Nutrition in 2024, investigated a polyphenol-rich formula based on nutrients naturally occurring in Tartary buckwheat. Jeffrey Bland was among the authors, along with Austin Perlmutter and researchers affiliated with TruDiagnostic.

The researchers were not asking whether people felt younger or had more energy. They were looking for measurable changes in epigenetic aging, immune-cell patterns, and biological pathways associated with immune function and aging.

The results are promising enough to be interesting, but nuanced enough that the details deserve more attention than the headline.

What the Big Bold Health Longevity Study Tested

The study enrolled 50 generally healthy men and women between 18 and 85 years old. Forty participants remained in the final per-protocol analysis.

For 90 days, participants took HTB Rejuvenate, a concentrated polyphenol formula designed around the phytochemical profile of Himalayan Tartary Buckwheat.

The research dose was four capsules per day, divided into two capsules in the morning and two in the evening with food. That provided approximately 1,158 mg of the specified polyphenols per day, including quercetin, rutin, hesperidin, and luteolin.

This is worth noting because the research protocol should not automatically be interpreted as today's consumer dosing instructions. People using the current Big Bold Health HTB (Immune) Rejuvenate® should follow the current product label or instructions from their healthcare professional rather than copying a research protocol.

Blood samples were collected before and after the intervention. Researchers analyzed DNA methylation across roughly 850,000 CpG sites and calculated several established epigenetic aging measures, including PCPhenoAge, PCGrimAge, OMICmAge, and DunedinPACE.

They also used the methylation data to estimate changes in immune-cell populations and to look for biological pathways associated with the methylation changes.

Where the 47% Number Comes From

Big Bold Health has understandably highlighted one of the most striking findings from the paper: an approximately 47% reduction in epigenetic age acceleration.

The number comes directly from the published data, but it needs context.

The finding occurred in a subgroup of six participants whose baseline PCPhenoAge acceleration was more than one standard deviation above the study mean. Their average epigenetic age acceleration fell from 8.065 to 4.262 during the 90-day intervention.

For people beginning the study with faster aging by this particular clock, that is an intriguing signal.

It was not, however, a 47% reduction in biological aging across all 40 participants.

When the entire study population was analyzed together, PCPhenoAge acceleration did not change significantly. Whole-group changes in OMICmAge, PCGrimAge, and DunedinPACE were also not statistically significant.

There were even small subgroups at the opposite end of the spectrum in which certain age-acceleration measures increased.

That variability may ultimately become part of the more interesting story. Nutrition does not interact with every person identically. Baseline metabolic state, microbiome composition, immune-cell makeup, diet, exercise, genetics, and existing epigenetic patterns may all influence response.

The Epigenetic Findings Were Broader Than One Aging Clock

Focusing only on the 47% number misses much of the paper.

Across the genome-wide methylation analysis, researchers identified 887 differentially methylated CpG sites between baseline and the end of the 90-day intervention.

Of those, 336 became more methylated and 551 became less methylated.

DNA methylation is one of the mechanisms cells use to regulate gene activity. A methylation change is not automatically beneficial or harmful; its meaning depends on where it occurs and what biological processes are associated with that region.

The researchers therefore mapped those methylation changes to gene-ontology pathways, looking for patterns in the biological systems most strongly represented.

That analysis produced signals touching immune regulation, cellular differentiation, neural biology, protein regulation, and pathways related to aging biology.

This is exploratory work. It does not mean researchers demonstrated that hundreds of genes had been permanently switched into a younger state. It does show that the nutritional intervention was associated with measurable changes across the epigenome.

For a 90-day food-derived intervention, that is interesting.

Why the CERK Finding Is Interesting

The largest pathway enrichment reported in the hypermethylated analysis involved ceramide kinase, or CERK.

Ceramides are signaling lipids found in cell membranes. They participate in metabolic regulation, immune signaling, cellular stress responses, inflammation, and other aspects of cell biology.

Ceramide biology has also attracted considerable interest in cardiometabolic research because abnormal ceramide accumulation has been associated with insulin resistance and cardiovascular risk.

CERK converts ceramide into ceramide-1-phosphate, another signaling lipid involved in immune and inflammatory responses.

The gene-ontology analysis found approximately 22-fold enrichment for ceramide kinase-related activity among the relevant methylation sites.

This should not be interpreted as saying HTB Rejuvenate increased or decreased human CERK enzyme activity by 22-fold. The study measured methylation patterns and pathway enrichment, not a 22-fold change in circulating ceramide kinase itself.

Even with that caveat, the signal is worth following. The intersection of dietary polyphenols, sphingolipid metabolism, immune signaling, and metabolic health is a biologically credible area of research.

The study also identified enrichment involving the COP9 signalosome, a protein complex involved in cellular regulation, protein turnover, and cell-cycle biology.

What Happened to Immune-Cell Markers?

The researchers also estimated immune-cell populations from the epigenetic data.

Several statistically significant changes appeared in different subgroups. Among participants starting with higher PCPhenoAge acceleration, CD4 and CD8 memory T-cell estimates increased. Other subgroups showed changes in natural killer cells, naïve B cells, and basophils.

These findings add another layer to the study because aging of the immune system, often referred to as immunosenescence, involves changes not only in inflammation but also in the distribution and behavior of different immune-cell populations.

Still, the study did not demonstrate that participants became resistant to infections or developed clinically stronger immunity. These were biomarker and estimated cell-population changes, not clinical endpoints.

That is a reasonable place for an early study to begin.

Why Himalayan Tartary Buckwheat?

Himalayan Tartary Buckwheat has become a major focus of Dr. Jeffrey Bland's more recent work because of its unusually rich phytochemical profile.

It naturally contains rutin along with quercetin, luteolin, hesperidin, d-chiro-inositol, and other plant compounds.

For years, polyphenols were discussed mainly as antioxidants. That explanation is increasingly incomplete. These molecules can interact with the microbiome, cellular signaling, inflammatory pathways, enzymes, epigenetic regulation, and microbial metabolites.

Much of what humans consume never acts as an isolated molecule. Food arrives as a matrix.

That larger idea runs through much of Dr. Jeffrey Bland's work in systems biology and personalized longevity medicine: nutrition is not simply a matter of replacing individual deficiencies. Food creates a complex stream of biological inputs.

For readers interested in the broader science, our article on polyphenols, immunometabolism, and longevity medicine explores that relationship in more detail.

We also take a closer look at the current product itself in HTB Rejuvenate, Polyphenols, and Immune-Metabolic Resilience.

The Microbiome May Be Part of the Story

One particularly interesting question raised by the authors involves the microbiome.

Many polyphenols are incompletely absorbed in the small intestine. They reach the colon, where gut microorganisms transform them into additional metabolites. Those metabolites can then interact with immune cells, intestinal tissues, and metabolic pathways.

The authors specifically identify the microbiome as an important area for future research because individual microbial communities may help explain why people respond differently to polyphenol interventions.

That connection is also why Big Bold Health's broader approach extends beyond concentrated HTB polyphenols. Microbiome Rejuvenate® is built around the relationship between whole-food polyphenols and the intestinal ecosystem, while HTB Rejuvenate® Superfood uses Himalayan Tartary Buckwheat in a food-based powder format.

Neither product was tested in this 90-day trial. They belong to the same nutritional philosophy, not the same clinical evidence base.

Whole-Food Complexity Beyond HTB

The same food-matrix thinking appears elsewhere in Big Bold Health's product line.

Omega-3 Rejuvenate®, for example, uses minimally processed salmon and cod oils rather than treating omega-3 nutrition solely as a race for the largest EPA and DHA number.

That has nothing to do with the HTB Longevity Study itself, but the philosophical connection is clear: naturally occurring nutrients may behave differently when delivered within a broader biological matrix.

We explored that separately in our Omega-3 Rejuvenate review.

What the Study Can and Cannot Tell Us

This was an encouraging pilot study, not a definitive longevity trial.

There was no placebo group. Participants knew they were taking the supplement. Forty people remained in the final per-protocol analysis. Lifestyle variables such as sleep, exercise, stress, and everyday dietary fluctuations were not tightly controlled.

The investigators themselves acknowledge these limitations and call for larger, more controlled studies.

There is also commercial involvement worth knowing about. Big Bold Health funded the study, and several authors were employees or consultants of Big Bold Health or TruDiagnostic.

Industry funding does not make a study invalid. Nutrition and pharmaceutical research are routinely funded by companies developing the intervention being tested. It does make independent replication especially valuable.

The other point is more fundamental: an epigenetic clock is a biomarker.

Changes in a methylation-based aging algorithm are scientifically interesting, but they are not equivalent to proving that someone will live longer, avoid cardiovascular disease, preserve cognition, or remain healthier for another decade.

Those questions require much larger studies and much longer follow-up.

The HormoneSynergy® Perspective

We like this study.

Not because it proves that a capsule can reverse aging, but because it asks a better nutritional question.

Can naturally occurring combinations of plant compounds produce measurable effects across interconnected biological systems in humans?

In this small study, the answer appears to be yes. The researchers detected changes in DNA methylation, immune-cell patterns, and cellular pathways over only 90 days.

The finding among people entering the study with higher PCPhenoAge acceleration is especially intriguing and deserves follow-up. So do the CERK findings and the apparent variability in individual response.

We would simply stop short of turning those results into the claim that Himalayan Tartary Buckwheat has been proven to make humans age 47% more slowly.

That is not what the study established.

The stronger conclusion is also the more interesting one: a polyphenol-rich nutritional intervention produced measurable biological signals in humans, and some of those signals intersect with immune aging, metabolism, and epigenetic regulation.

For an initial human trial, that is a good place to be.

Food Still Has the Larger Evidence Base

No discussion of polyphenols should end with a supplement bottle.

Mediterranean-style eating patterns rich in vegetables, berries, legumes, herbs, spices, nuts, seeds, olive oil, tea, coffee, and other minimally processed plant foods provide enormous polyphenol diversity alongside fiber, minerals, fatty acids, and thousands of additional food compounds.

The study authors themselves frame their work within a larger "food is medicine" discussion.

Himalayan Tartary Buckwheat may prove to be an unusually interesting food within that conversation. The research so far makes it worth following.

But the practical hierarchy remains familiar: eat well, preserve muscle, exercise, sleep, maintain metabolic health, address cardiovascular risk, avoid smoking, manage blood pressure, and use targeted nutritional support where it adds something useful.

That is a far less dramatic prescription than claiming one plant slows aging by 47%.

It is also much closer to how longevity works.

Study Reference

Perlmutter A, Bland JS, Chandra A, et al. The impact of a polyphenol-rich supplement on epigenetic and cellular markers of immune age: a pilot clinical study. Frontiers in Nutrition. 2024;11:1474597. doi:10.3389/fnut.2024.1474597. ClinicalTrials.gov identifier NCT05234203.

Frequently Asked Questions

What is the Big Bold Health Longevity Study?

It was a 90-day pilot clinical study examining the effects of a polyphenol-rich HTB Rejuvenate formula on DNA methylation, epigenetic aging measures, estimated immune-cell populations, and biological pathways in generally healthy adults.

Did HTB Rejuvenate slow aging by 47%?

A subgroup of six participants who began the study with higher PCPhenoAge acceleration experienced an approximately 47% reduction in that particular epigenetic-age acceleration measure. The entire study population did not experience a statistically significant 47% slowing of aging.

How many people were in the study?

Fifty adults were enrolled. Forty participants were included in the final per-protocol laboratory analysis.

How much HTB Rejuvenate did participants take?

Participants took four capsules per day, two in the morning and two in the evening with food, during the 90-day study. This was the research protocol and should not be substituted for current product-label directions or individualized medical advice.

What is epigenetic age?

Epigenetic-age algorithms estimate aspects of biological aging by analyzing patterns of DNA methylation. They are useful research biomarkers, but a change in an epigenetic clock does not by itself prove that someone will live longer or avoid age-related disease.

Was the study placebo controlled?

No. It was a single-arm, open-label pilot trial. The absence of a placebo group is an important limitation and one reason larger controlled studies are needed.

Did the study test Microbiome Rejuvenate or Omega-3 Rejuvenate?

No. The published study tested HTB Rejuvenate. Microbiome Rejuvenate® and Omega-3 Rejuvenate® are separate Big Bold Health products and should not be assumed to have the same clinical evidence.

Does HormoneSynergy® consider the study promising?

Yes. The study provides interesting early human evidence involving epigenetic, immune-cell, and biological-pathway changes after a polyphenol-rich nutritional intervention. We view the findings as promising preliminary research that warrants larger, independent, placebo-controlled trials.

*These statements have not been evaluated by the Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease.